Literature DB >> 2013239

In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.

G Morace1, S Manzara, G Dettori.   

Abstract

The in vitro activity of fluconazole was tested against 13 yeast species (119 strains) isolated from clinical specimens during a 3-month period. For comparative purposes, three other antifungal compounds (5-fluorocytosine, amphotericin B and ketoconazole) were also tested. The tests were carried out using a microautomated method previously developed in our laboratory. The method allowed us to determine the minimum inhibitory concentration (MIC) of the four antifungal drugs used. For each of the drugs we utilized different media. The MIC ranges (mg/l) of fluconazole were: 0.04-12.5 for Candida albicans, 0.19-6.25 for Candida parapsilosis, 12.5-50 for Candida krusei, 0.04-100 for Candida tropicalis, 0.04- greater than 100 for Candida glabrata, 0.09- greater than 25 for Cryptococcus neoformans, 0.09-0.78 for Saccharomyces cerevisiae, 6.25- greater than 100 for Trichosporon beigelii and 0.09-0.19 for Blastoschizomyces capitatus (Trichosporon capitatum). The MIC value (mg/l) was 0.39 for Candida guilliermondii and Candida lusitaniae, greater than 100 for Cryptococcus laurentii and 0.09 for the 3 isolates of Torulopsis candida. These results were obtained using the medium recommended for in vitro testing of fluconazole (high-resolution medium) by Pfizer UK.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013239     DOI: 10.1159/000238828

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  13 in total

1.  Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients.

Authors:  D D'Antonio; A Mazzoni; A Iacone; B Violante; M A Capuani; F Schioppa; F Romano
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

2.  Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS.

Authors:  Esaki Muthu Shankar; Nagalingeswaran Kumarasamy; Devaleenol Bella; Srinivasan Renuka; Hayak Kownhar; Solomon Suniti; Ramachandra Rajan; Usha Anand Rao
Journal:  Can Respir J       Date:  2006 Jul-Aug       Impact factor: 2.409

3.  Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis.

Authors:  J Fortún; A López-San Román; J J Velasco; A Sánchez-Sousa; E de Vicente; J Nuño; C Quereda; R Bárcena; G Monge; A Candela; A Honrubia; A Guerrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  Rationale for selective use of anaerobic blood cultures.

Authors:  A J Morris; M L Wilson; S Mirrett; L B Reller
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

Review 5.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

6.  Candida esophagitis complicated by an esophago-airway fistula: report of a case.

Authors:  Ryu Kanzaki; Masahiko Yano; Ko Takachi; Shingo Ishiguro; Masaaki Motoori; Kentaro Kishi; Isao Miyashiro; Osamu Ishikawa; Shingi Imaoka
Journal:  Surg Today       Date:  2009-11-01       Impact factor: 2.549

7.  Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity.

Authors:  E Anaissie; R Hachem; C K-Tin-U; L C Stephens; G P Bodey
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

Review 8.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.

Authors:  N C Karyotakis; M C Dignani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Effect of amphotericin B on the lipids of five different strains of Cryptococcus neoformans.

Authors:  S P Franzot; J S Hamdan
Journal:  Mycopathologia       Date:  1994-11       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.